Calamos Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.11M | Hold |
11,793
| – | – | 0.03% | 424 |
|
|
2025
Q4 | $9.1M | Sell |
11,793
-479
| -4% | -$325K | 0.03% | 419 |
|
|
2025
Q3 | $6.9M | Hold |
12,272
| – | – | 0.03% | 490 |
|
|
2025
Q2 | $6.44M | Hold |
12,272
| – | – | 0.03% | 512 |
|
|
2025
Q1 | $7.78M | Sell |
12,272
-10,386
| -46% | -$7.14M | 0.03% | 443 |
|
|
2024
Q4 | $16.1M | Buy |
22,658
+10,523
| +87% | +$8.83M | 0.07% | 295 |
|
|
2024
Q3 | $12.8M | Sell |
12,135
-298
| -2% | -$332K | 0.06% | 355 |
|
|
2024
Q2 | $13.1M | Sell |
12,433
-454
| -4% | -$440K | 0.06% | 345 |
|
|
2024
Q1 | $12.4M | Sell |
12,887
-324
| -2% | -$308K | 0.06% | 347 |
|
|
2023
Q4 | $11.6M | Sell |
13,211
-173
| -1% | -$142K | 0.06% | 356 |
|
|
2023
Q3 | $11M | Hold |
13,384
| – | – | 0.06% | 368 |
|
|
2023
Q2 | $9.62M | Hold |
13,384
| – | – | 0.05% | 429 |
|
|
2023
Q1 | $11M | Sell |
13,384
-1,687
| -11% | -$1.27M | 0.05% | 406 |
|
|
2022
Q4 | $10.9M | Sell |
15,071
-2,661
| -15% | -$1.96M | 0.05% | 438 |
|
|
2022
Q3 | $12.2M | Sell |
17,732
-18
| -0.1% | -$11.3K | 0.06% | 404 |
|
|
2022
Q2 | $10.5M | Buy |
17,750
+493
| +3% | +$320K | 0.05% | 468 |
|
|
2022
Q1 | $12.1M | Buy |
17,257
+2,315
| +15% | +$1.46M | 0.05% | 469 |
|
|
2021
Q4 | $9.44M | Buy |
14,942
+578
| +4% | +$355K | 0.04% | 516 |
|
|
2021
Q3 | $8.69M | Buy |
14,364
+1,268
| +10% | +$787K | 0.04% | 469 |
|
|
2021
Q2 | $7.32M | Buy |
13,096
+2,979
| +29% | +$1.51M | 0.03% | 484 |
|
|
2021
Q1 | $4.79M | Buy |
10,117
+313
| +3% | +$152K | 0.03% | 547 |
|
|
2020
Q4 | $4.74M | Sell |
9,804
-425
| -4% | -$229K | 0.03% | 507 |
|
|
2020
Q3 | $5.73M | Sell |
10,229
-911
| -8% | -$552K | 0.04% | 430 |
|
|
2020
Q2 | $6.95M | Sell |
11,140
-712
| -6% | -$404K | 0.05% | 372 |
|
|
2020
Q1 | $5.79M | Sell |
11,852
-979
| -8% | -$404K | 0.05% | 372 |
|
|
2019
Q4 | $4.82M | Sell |
12,831
-211
| -2% | -$71K | 0.02% | 528 |
|
|
2019
Q3 | $3.62M | Buy |
13,042
+1,131
| +9% | +$335K | 0.02% | 563 |
|
|
2019
Q2 | $3.73M | Buy |
11,911
+248
| +2% | +$82.6K | 0.02% | 567 |
|
|
2019
Q1 | $4.79M | Buy |
11,663
+459
| +4% | +$189K | 0.03% | 468 |
|
|
2018
Q4 | $4.18M | Buy |
11,204
+1,678
| +18% | +$614K | 0.03% | 481 |
|
|
2018
Q3 | $3.85M | Sell |
9,526
-5,122
| -35% | -$1.95M | 0.02% | 513 |
|
|
2018
Q2 | $5.05M | Sell |
14,648
-2,535
| -15% | -$793K | 0.03% | 433 |
|
|
2018
Q1 | $5.92M | Sell |
17,183
-103,083
| -86% | -$35.9M | 0.04% | 402 |
|
|
2017
Q4 | $45.2M | Buy |
120,266
+51,044
| +74% | +$20.7M | 0.23% | 93 |
|
|
2017
Q3 | $31M | Buy |
69,222
+57,538
| +492% | +$27.4M | 0.24% | 129 |
|
|
2017
Q2 | $5.74M | Buy |
11,684
+3,858
| +49% | +$1.69M | 0.04% | 358 |
|
|
2017
Q1 | $3.03M | Buy |
7,826
+3,811
| +95% | +$1.41M | 0.02% | 430 |
|
|
2016
Q4 | $1.47M | Sell |
4,015
-52
| -1% | -$19.8K | 0.01% | 535 |
|
|
2016
Q3 | $1.64M | Buy |
4,067
+4
| +0.1% | +$1.6K | 0.01% | 483 |
|
|
2016
Q2 | $1.42M | Buy |
4,063
+1
| +0% | +$385 | 0.01% | 499 |
|
|
2016
Q1 | $1.46M | Buy |
4,062
+253
| +7% | +$104K | 0.01% | 496 |
|
|
2015
Q4 | $2.07M | Hold |
3,809
| – | – | 0.01% | 462 |
|
|
2015
Q3 | $1.77M | Buy |
3,809
+1
| +0% | +$537 | 0.01% | 478 |
|
|
2015
Q2 | $1.94M | Sell |
3,808
-23,115
| -86% | -$11.3M | 0.01% | 486 |
|
|
2015
Q1 | $12.2M | Sell |
26,923
-167,202
| -86% | -$70.9M | 0.08% | 243 |
|
|
2014
Q4 | $79.6M | Sell |
194,125
-109,637
| -36% | -$43.1M | 0.53% | 54 |
|
|
2014
Q3 | $110M | Sell |
303,762
-20,395
| -6% | -$6.84M | 0.73% | 30 |
|
|
2014
Q2 | $91.6M | Sell |
324,157
-50,040
| -13% | -$14.8M | 0.58% | 44 |
|
|
2014
Q1 | $112M | Buy |
374,197
+40,069
| +12% | +$12.3M | 0.72% | 36 |
|
|
2013
Q4 | $92M | Sell |
334,128
-93
| -0% | -$26.7K | 0.58% | 43 |
|
|
2013
Q3 | $105M | Buy |
334,221
+11,695
| +4% | +$3.08M | 0.66% | 40 |
|
|
2013
Q2 | $72.5M | Buy |
+322,526
| New | +$75.1M | 0.47% | 58 |
|
Other funds holding REGN
VCM
N
Calamos Advisors's REGN Position: Q1 2026 in Review
Calamos Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 11,793 shares worth $9.11M. The position accounts for 0.03% of the portfolio, ranked #424.
Calamos Advisors first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $112M in Q1 2014. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Calamos Advisors held 11,793 shares of Regeneron Pharmaceuticals worth $9.11M as of Q1 2026.
- Calamos Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
- Regeneron Pharmaceuticals made up 0.03% of Calamos Advisors's portfolio in Q1 2026, its #424 holding.
- Calamos Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Calamos Advisors's Regeneron Pharmaceuticals position peaked at $112M in Q1 2014.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.